PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1391968
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1391968
The global real world data (RWD) market size is projected to grow from US$ 1.59 Bn in 2023 to US$ 4.07 Bn by 2030, at a CAGR of 14.4%.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 1.59 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 14.40% | 2030 Value Projection: | US$ 4.07 Bn |
Real world data plays a crucial role in understanding and addressing complex challenges across various fields. It refers to information gathered from real-life situations, such as demographics, economic indicators, healthcare records, environmental factors, and more. Unlike simulated or theoretical data, global real world data (RWD) offers insights into actual events, behaviours and trends. It enables researchers, policymakers and businesses to make informed decisions, develop accurate models, and implement effective strategies. With the advent of advanced technologies and the growing availability of large-scale data, global real world data (RWD) analysis has become increasingly valuable in uncovering patterns, identifying correlations, and generating actionable knowledge to drive innovation and improve outcomes in diverse domains. The real-world data market refers to the collection and analysis of data from various sources outside of traditional clinical trials. These sources can include electronic health records, insurance claims data, patient registries, and even data from wearable devices. This data is then used to inform healthcare decisions and strategies, improve patient outcomes, and drive innovation in the healthcare industry.
The increasing introduction of new products in the market is expected to drive the growth of the market over the forecast period. For instance, in November 2022, Castor, a leading provider of decentralized and hybrid clinical trial technology solutions, announced a new offering to simplify post-marketing clinical trials. By extending global reach, integrating real-world data (RWD), and automating trial processes, Castor's latest offering can reduce trial costs by 30% and deployment timelines to only 4 weeks on average.
However, data quality and completeness, data privacy and regulatory compliance, data fragmentation, and interoperability and selection bias and generalizability are expected to hamper growth of the global real world data (RWD) market over the forecast period.